Abstract: Bispecific antigen binding molecules (e.g., antibodies) that bind blood clotting factors, factor IXa (FIXa) and factor X (FX), and enhance the FIXa-catalysed activation of FX to FXa. Use of the bispecific antigen binding molecules to control bleeding, by replacing natural cofactor FVIIIa which is deficient in patients with haemophilia A.
Type:
Grant
Filed:
October 6, 2020
Date of Patent:
May 7, 2024
Assignee:
KYMAB LIMITED
Inventors:
Wei Wang, E-Chiang Lee, John Kenneth Blackwood, Roberto Magliozzi
Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
Type:
Grant
Filed:
June 20, 2017
Date of Patent:
April 23, 2024
Assignee:
KYMAB LIMITED
Inventors:
Jamie Campbell, Nikole Sandy, Cassandra Van Krinks, Stephen John Arkinstall, Volker Germaschewski, Ian Kirby, Miha Kosmac, Thomas Gallagher, Cecilia Deantonio, Stephen Douglas Gillies
Abstract: The invention relates to an approach for introducing one or more desired insertions and/or deletions of known sizes into one or more predefined locations in a nucleic acid (eg, in a cell or organism genome). They developed techniques to do this either in a sequential fashion or by inserting a discrete DNA fragment of defined size into the genome precisely in a predefined location or carrying out a discrete deletion of a defined size at a precise location. The technique is based on the observation that DNA single-stranded breaks are preferentially repaired through the HDR pathway, and this reduces the chances of indels (eg, produced by NHEJ) in the present invention and thus is more efficient than prior art techniques. The invention also provides sequential insertion and/or deletions using single- or double-stranded DNA cutting.
Abstract: Bispecific antigen binding molecules (e.g., antibodies) that bind blood clotting factors, factor IXa (FIXa) and factor X (FX), and enhance the FIXa-catalysed activation of FX to FXa. Use of the bispecific antigen binding molecules to control bleeding, by replacing natural cofactor FVIIIa which is deficient in patients with haemophilia A.
Type:
Grant
Filed:
June 22, 2018
Date of Patent:
March 5, 2024
Assignee:
KYMAB LIMITED
Inventors:
Wei Wang, E-Chiang Lee, John Kenneth Blackwood, Roberto Magliozzi
Abstract: The invention relates to a protein for use in diagnosing and treating primary or secondary sclerosing diseases, a fusion protein, and nucleotide sequence and a vector, and to a pharmaceutical composition for use in diagnosing and treating primary or secondary sclerosing diseases.
Type:
Grant
Filed:
June 14, 2018
Date of Patent:
January 23, 2024
Assignee:
Kymab Limited
Inventors:
Martina Rauner, Lorenz C. Hofbauer, Uwe Platzbecker, Ulrike Baschant
Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.
Type:
Grant
Filed:
August 9, 2017
Date of Patent:
January 2, 2024
Assignee:
KYMAB LIMITED
Inventors:
Richard Charles Alfred Sainson, Stephen John Arkinstall, Jamie Iain Campbell, Mohammed Hanif Ali, E-Chiang Lee, Matthew John McCourt, Volker Germaschewski, Ian Kirby, Miha Kosmac, Nahida Parveen, Robert Rowlands, Gwenoline Borhis
Abstract: The invention relates to the provision of antibody therapeutics and prophylactics that are tailored specifically for human use. The present invention provides libraries, vertebrates and cells, such as transgenic mice or rats or transgenic mouse or rat cells. Furthermore, the invention relates to methods of using the vertebrates to isolate antibodies or nucleotide sequences encoding antibodies. Antibodies, heavy chains, polypeptides, nucleotide sequences, pharmaceutical compositions and uses are also provided by the invention.
Type:
Grant
Filed:
May 28, 2020
Date of Patent:
November 21, 2023
Assignee:
Kymab Limited
Inventors:
Allan Bradley, Glenn Friedrich, E-Chiang Lee, Mark Strivens, Nicholas England
Abstract: The present invention relates to combinations comprising anti-human x OX40L antibodies, new biomarkers of autoimmune or alloimmune deseases, and their use in various therapeutic methods.
Type:
Grant
Filed:
November 3, 2017
Date of Patent:
October 10, 2023
Assignee:
KYMAB LIMITED
Inventors:
Philip Bland-Ward, Leslie Kean, Victor Tkachev
Abstract: The invention relates to treating or preventing anaemia in a subject, such as a mammal or human. In particular, the invention addresses moderate to severe anaemia. Additionally, the invention provides means for sparing administration of erythropoiesis stimulating agents (ESAs) to subjects.
Type:
Application
Filed:
August 11, 2022
Publication date:
July 27, 2023
Applicant:
Kymab Limited
Inventors:
Volker GERMASCHEWSKI, Igor THEURL, Martin YATEMAN, Jasper CLUBE, Steve ARKINSTALL
Abstract: The present invention is directed to the concept of sectoring antibody gene segment repertoires in order to enable the development of novel, synthetic antibody chain repertoires not seen in nature. The present invention is also directed to the realisation of the inventors that sectoring can also alter gene segment expression by providing new arrangements of gene segment clusters relative to other gene segments and regulatory elements in transgenic immunoglobulin loci, thereby providing for new synthetic antibody chain sequence repertoires. The invention also relates to gene segment inversion.
Abstract: The present invention relates to anti-OPG antibodies, and to methods of treatment, uses and pharmaceutical compositions comprising such antibodies, for example in the treatment and prevention of PAH.
Type:
Grant
Filed:
January 26, 2018
Date of Patent:
June 20, 2023
Assignee:
KYMAB LIMITED
Inventors:
Joana De Abreu Carvalho, Steve Holmes, Allan Lawrie
Abstract: The invention relates to treating or preventing anaemia in a subject, such as a mammal or human. In particular, the invention addresses moderate to severe anaemia. Additionally, the invention provides means for sparing administration of erythropoiesis stimulating agents (ESAs) to subjects.
Type:
Grant
Filed:
June 1, 2017
Date of Patent:
May 16, 2023
Assignee:
Kymab Limited
Inventors:
Volker Germaschewski, Igor Theurl, Martin Yateman, Jasper Clube, Steve Arkinstall
Abstract: Multispecific antibody in mAb2 format, comprising an ICOS-binding Fab region and a PD-L1-binding Fcab region. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours. Combination therapy including antibody to another immune checkpoint molecule such as PD-1 and CTLA-4, in addition to anti-ICOS and anti-PD-L1.
Type:
Grant
Filed:
December 19, 2018
Date of Patent:
April 18, 2023
Assignee:
KYMAB LIMITED
Inventors:
Matthew John McCourt, Richard Charles Alfred Sainson, Jamie Iain Campbell, Stephen John Arkinstall, Mihriban Tuna, Ryan Fiehler, Mustapha Faroudi, Fadi Badr, Francisca Wollerton Van Horck, Frederick Akele
Abstract: The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.
Type:
Grant
Filed:
August 9, 2016
Date of Patent:
March 21, 2023
Assignee:
Kymab Limited
Inventors:
Allan Bradley, E-Chiang Lee, Qi Liang, Wei Wang, Glenn Friedrich
Abstract: The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.
Type:
Grant
Filed:
August 4, 2015
Date of Patent:
January 31, 2023
Assignee:
Kymab Limited
Inventors:
Allan Bradley, E-Chiang Lee, Qi Liang, Wei Wang, Glenn Friedrich
Abstract: The present invention relates to antibodies specific for one or more antigens, bispecific antibodies containing one or more domains with specificity to the target(s), and to immunocytokines. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
Type:
Grant
Filed:
June 20, 2018
Date of Patent:
September 13, 2022
Assignee:
KYMAB LIMITED
Inventors:
Joana de Abreu Carvalho, Rachael Jane Kimber, Jamie Ian Campbell, Nikole Sandy, Cassandra Van Krinks, Stephen John Arkinstall, Volker Germaschewski, Ian Kirby, Miha Kosmac, Thomas Gallagher, Matthew John McCourt, Richard Charles Alfred Sainson, Mohammed Hanif Ali, E-Chiang Lee, Stephen Douglas Gillies